The utility of structure-based virtual screening combined with ADMET prediction as an effective strategy for early-stage lead identification in prostate cancer drug discovery and the improved predicted pharmacokinetic properties suggest that rational modification of heterocyclic scaffolds can yield AR antagonists with superior drug-like profiles.
Abstract
Prostate cancer is one of the most prevalent malignancies and
the second leading cause of cancer-related death in men after cardiovascular diseases. Currently
available therapies, such as bicalutamide, suffer from limitations, including off-target effects and
resistance, highlighting the urgent need for novel androgen receptor (AR) inhibitors with improved
binding affinity, pharmacokinetic properties, enhanced efficacy, and reduced adverse effects.
On the basis of its structural similarity to bicalutamide, virtual screening of
the PubChem database yielded 100 heterocyclic compounds. These molecules were subjected to
molecular docking against the androgen receptor (PDB ID: 1Z95) via AutoDock Vina to evaluate
binding interactions. The docking accuracy was validated using root-mean-square deviation (RMSD)
analysis and comparison with the co-crystallized ligand. The top 10 ligands with the highest binding
affinities were further assessed for their absorption, distribution, metabolism, excretion, and toxicity
(ADMET) profiles via pkCSM and the Toxicity Estimation Software Tool (TEST).
Docking studies identified HARIc-001 as the most potent AR inhibitor, with a binding energy
of −10.30 kcal/mol, which was greater than that of bicalutamide (−9.00 kcal/mol). Key hydrogen
bonding interactions with Lys808 and Asn756 contributed to the increased binding affinity of
this protein. ADMET analysis revealed that HARIc-001 had superior predicted intestinal absorption
(91.5%) compared to bicalutamide (81.3%), along with favorable solubility, metabolic stability, and
toxicity profiles, supporting its potential oral bioavailability and safety.
The enhanced binding affinity of HARIc-001 relative to bicalutamide may be attributed
to stronger hydrogen bonding and optimized interactions within the AR ligand-binding pocket. The
improved predicted pharmacokinetic properties further suggest that rational modification of heterocyclic
scaffolds can yield AR antagonists with superior drug-like profiles. These findings support the
utility of structure-based virtual screening combined with ADMET prediction as an effective strategy
for early-stage lead identification in prostate cancer drug discovery.
This study highlights HARIc-001 as a promising novel AR antagonist with improved
binding affinity and favorable pharmacokinetic characteristics compared with bicalutamide. The
results provide a foundation for subsequent in vitro and in vivo validation, structural optimization,
and preclinical development of next-generation AR inhibitors for prostate cancer therapy.
VS-04 was identified as a promising oxadiazole–pyrazole lead with potent antiproliferative activity against prostate cancer cells, which was associated with AR modulation, oxidative stress, cell-cycle perturbation, and apoptotic cell death.
The improved binding affinity of the designed derivatives compared to scopoletin suggests that structural modifications of the coumarin nucleus enhanced their interaction with Topoisomerase IIα, a crucial enzyme involved in DNA replication and a validated target in cancer therapy.
A. Pandey, Anuvanshika Yadav, Anupam Tiwari et al.· Biological sciences· 0 citations
Prostate cancer is a leading cause of mortality among men worldwide and is a disease characterized by genetic and epidemiological heterogeneity. Androgen receptors play a pivotal role in the pathogenesis and progression of prostate cancer to its aggressive form. Studies indicate that combining chemotherapy with androge...
Hussein Kareem Kadhim, D. Z. Mutlaq· Adolescência e Saúde· 0 citations
The combined in silico in vitro strategy was found to be useful in expediting anticancer lead discovery, and it aids in using computational-experimental pipelines in rational drug design.
Z. Al-Khazragie, Mayada Sabri, Luma Sabri et al.· Babcock University Medical J...· 0 citations
Results indicate that perimidine-based molecules, particularly Compound 101 and Compound 201, are promising compounds towards the development as EGFR-targeting anticancer drugs; however, further biochemical and cellular target-validation studies are required to confirm direct EGFR inhibition and their therapeutic poten...
M. Gopinadh, Sreehari A. P., S. S et al.· Naunyn-Schmiedeberg's Archiv...· 0 citations
ABSTRACT Oestrogen receptor alpha (ERα) is a driver of hormone-dependent breast cancer, yet current therapies are often hindered by drug resistance and adverse effects. In this study, we developed a structure-based virtual screening workflow to identify novel quinoxaline derivatives as computationally prioritized poten...
A. Sharma, D. Kumar, B. Narasimhan et al.· SAR and QSAR in environmenta...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.